Serum Lipoprotein Composition in Different Types of Hyperlipoproteinemia

  • Lars A. Carlson
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 63)


At present the six types of hyperlipoproteinemia (HLP) defined in the WHO memorandum (1) as an extension of the typing system of Fredricks on et al (Z) is in common use. According to this memorandum the diagnosis of a type of HLP is based upon “elevation” of one or more of the following lipoprotein (LP) classes: chylomicrons, very low density LP (VLDL) and low density LP (LDL). This may seem simple and clear but there are many difficulties involved. One major problem is to define “elevated.” This definition may certainly vary depending on its purpose, which for example can be clinical (diagnostic, treatment), epidemiological, genetic, physiological, etc. The definition of “normal” and “elevated” may furthermore vary with factors such as age, sex, season, etc. Whatever the purpose is for definition of normal values we prefer to use the statistical method with construction of cumulative frequency curves for reasons discussed in detail elsewhere (3). With these curves it is easy to find the lipid level corresponding to a given percentile of the control (normal) population. In the study to be described we have for clinical purpose used the upper 90th percentile as an upper “normal” limit, values above are then considered elevated.


Cholesterol Content Familial Hypercholesterolemia Triglyceride Content Karolinska Hospital Lipid Clinic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beaumont, J. L., Carlson, L. A., Cooper, G. R., Fejfar, Z., Fredrickson, D.S. and Strasser, T. Bull. Wld. Hlth Org. Org. Mond. Sante 43: 891, 1970.Google Scholar
  2. 2.
    Fredrickson, D. S., Levy, R. I. and Lees, R. S. New England J. Med. 276: 34, 94, 148, 215, 273; 1967.CrossRefGoogle Scholar
  3. 3.
    Carlson, L. A. and Ericsson, M. Atherosclerosis 21, in press.Google Scholar
  4. 4.
    Carlson, K. J. Clin. Path. 26, Suppl. 5: 32, 1973.Google Scholar
  5. 5.
    Noble, R. P. J. Lipid Res. 9:693, 1968.PubMedGoogle Scholar
  6. 6.
    Ellefson, R. D., Jimenez, B. S. and Smith, R. C. Mayo Clinic Proc. 46: 328, 1971.Google Scholar
  7. 7.
    Hazzard, W. R., Porte, D. and Bierman, E. L. Metabolism 21: 1009, 1972.PubMedCrossRefGoogle Scholar
  8. 8.
    Carlson, K. and Carlson, L. A. Scand. J. Clin. Lab. Invest., in press.Google Scholar
  9. 9.
    Wiegandt, H., Lipp, K. and Wendt, G. G. Physiol. Chem. 349: 489, 1968.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1975

Authors and Affiliations

  • Lars A. Carlson
    • 1
  1. 1.King Gustaf V Research InstituteKarolinska HospitalStockholmSweden

Personalised recommendations